医学
更年期
背景(考古学)
激素疗法
雌激素
疾病
孕激素
妇科
临床试验
激素替代疗法(女性对男性)
重症监护医学
内科学
乳腺癌
癌症
古生物学
睾酮(贴片)
生物
作者
Leslie Cho,Andrew M. Kaunitz,Stephanie S. Faubion,Sharonne N. Hayes,Emily S. Lau,Nicole Pristera,Nandita S. Scott,Jan L. Shifren,Chrisandra Shufelt,Cynthia A. Stuenkel,Kathryn J. Lindley
出处
期刊:Circulation
[Ovid Technologies (Wolters Kluwer)]
日期:2023-02-14
卷期号:147 (7): 597-610
被引量:13
标识
DOI:10.1161/circulationaha.122.061559
摘要
Menopausal hormone therapy (HT) was widely used in the past, but with the publication of seminal primary and secondary prevention trials that reported an excess cardiovascular risk with combined estrogen-progestin, HT use declined significantly. However, over the past 20 years, much has been learned about the relationship between the timing of HT use with respect to age and time since menopause, HT route of administration, and cardiovascular disease risk. Four leading medical societies recommend HT for the treatment of menopausal women with bothersome menopausal symptoms. In this context, this review, led by the American College of Cardiology Cardiolovascular Disease in Women Committee, along with leading gynecologists, women's health internists, and endocrinologists, aims to provide guidance on HT use, including the selection of patients and HT formulation with a focus on caring for symptomatic women with cardiovascular disease risk.
科研通智能强力驱动
Strongly Powered by AbleSci AI